14-3-3 CSF levels in sporadic Creutzfeldt-Jakob disease differ across molecular subtypes

Neurobiology of Aging

Volumn 30, Issue 11, 2009, Pages 1842-1850

  Gmitterova K ^a,b   Heinemann, U ^a   Bodemer, M ^a   Krasnianski, A ^a   Meissner, B ^a   Kretzschmar, H A ^c   Zerr, I ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Physics and Informatics   (Slovakia)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

14 3 3 protein; Creutzfeldt Jakob disease; CSF; Dementia

Indexed keywords

PRION PROTEIN; PROTEIN 14 3 3;

ARTICLE; CLINICAL FEATURE; CODON; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; SENSITIVITY ANALYSIS;

14-3-3 PROTEINS; AGED; CREUTZFELDT-JAKOB SYNDROME; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PRIONS; PRPSC PROTEINS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 70049114839     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2008.01.007     Document Type: Article

References (42)

1. Aitken A., Collinge D.B., Van Heusden B.P., Isobe T., Roseboom P.H., Rosenfeld G., and Soll J. 14-3-3 proteins: a highly conserved, widespread family of eukaryotic proteins. Trends Biochem. Sci. 17 (1992) 498-501
2. Aksamit Jr. A.J., Preissner C.M., and Homburger H.A. Quantitation of 14-3-3 and neuron-specific enolase proteins in CSF in Creutzfeldt-Jakob disease. Neurology 57 (2001) 728-730
3. Beaudry P., Cohen P., Brandel J.P., Delasnerie-Laupretre N., Richard S., Launay J.M., and Laplanche J.L. 14-3-3 protein, neuron-specific enolase, and S-100 protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Dement. Geriatr. Cogn. Disord. 10 (1999) 40-46
4. Broadie K., Rushton E., Skoulakis E., and Davis R. Leonardo, a Drosophila 14-3-3 protein involved in learning, regulates presynaptic function. Neuron 2 (1997) 391-402
5. Castellani R.J., Colucci M., Xie Z., Zou W., Li C., Parchi P., Capellari S., Pastore M., Rahbar M.H., Chen S.G., and Gambetti P. Sensitivity of 14-3-3 protein test varies in subtypes of sporadic Creutzfeldt-Jakob disease. Neurology 63 (2004) 436-442
6. Collins S.J., Sanchez-Juan P., Masters C.L., Klug G.M., van Duijn C., Poleggi A., Almonti S., Cuadrado-Corrales N., de Pedro-Cuesta J., Budka H., Gelpi E., Glatzel M., Seeger H.E., Zerr I., Kretzschmar H., Jansen G.H., Olsen E., Mitrova E., Alpérovitsch A., Brandel J.P., Murray K., and Will R.G. Determinatinants of diagnostic investigation results across the clinical spectrum of sporadic CJD. Brain 129 (2006) 2278-2287
7. Gambetti P., Kong Q., Zou W., Parchi P., and Chen S. Sporadic and familial CJD: classification and characterisation. Br. Med. Bull. 66 (2003) 213-239
8. Geschwind M., Martindale J., Miller D., De Armond S.J., Uyehara-Lock J., Gaskin D., Kramer J.H., Barbaro N.M., and Miller B.L. Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt-Jakob disease. Arch. Neurol. 60 (2003) 813-816
9. Green A.J., Ramljak S., Muller W.E., Knight R.S., and Schroder H.C. 14-3-3 in the cerebrospinal fluid of patients with variant and sporadic Creutzfeldt-Jakob disease measured using capture assay able to detect low levels of 14-3-3 protein. Neurosci. Lett. 324 (2002) 57-60
10. Green A.J., Thompson E.J., Stewart G.E., Zeidler M., McKenzie J.M., MacLeod M.-A., Ironside J.W., Will R.G., and Knight R.S. Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease. J. Neurol. Neurosurg. Psychiatry 70 (2001) 744-748
11. HaÏk S., Brandel J.P., Sazdovitch V., Delasnerie-Lauprêtre N., Peoc'h K., Laplanche J.-L., Privat N., Duyckaerts C., Kemeny J.L., Kopp N., Laquerrière A., Mohr M., Deslys J.P., Dormont D., and Hauw J.J. Dementia with Lewy bodies in a neuropathologic series of suspected Creutzfeldt-Jakob disease. Neurology 55 (2000) 1401-1404
12. Harrington M., and Merril C. Cerebrospinal fluid protein analysis in diseases of the nervous system. J. Chromatogr. 429 (1988) 345-358
13. Harrington M.G., Merril C.R., Asher D.M., and Gajdusek D.C. Abnormal proteins in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. N. Engl. J. Med. 315 (1986) 279-283
14. Hsich G., Kenney K., Gibbs Jr. C.J., Lee K.H., and Harrington M.G. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongifrom encephalopathies. N. Engl. J. Med. 335 (1996) 924-930
15. Jimi T., Wakayama Y., Shibuya S., Nakata H., Tomaru T., Takahashi Y., Kosaka K., Asano T., and Kato K. High levels of nervous system-specific proteins in cerebrospinal fluid in patients with early stage Creutzfeldt-Jakob disease. Clin. Chim. Acta 211 (1992) 37-46
16. Kenney K., Brechtel C., Takahashi H., Kurohara K., Anderson P., and Gibbs Jr. C.J. An enzyme-linked immunosorbent assay to quantify 14-3-3 proteins in the cerebrospinal fluid of suspected Creutzfeldt-Jakob disease patients. Ann. Neurol. 48 (2000) 395-398
17. Kohira I., Tsuji T., Ishizu H., Takao Y., Wake A., Abe K., and Kuroda S. Elevation of neuron-specific enolase in serum and cerebrospinal fluid of early stage Creutzfeldt-Jakob disease. Acta Neurol. Scand. 102 (2000) 385-387
18. Krasnianski A., Schulz-Schaeffer W.J., Kallenberg K., Meissner B., Collie D.A., Roeber S., Bartl M., Heinemann U., Varges D., Kretzschmar H.A., and Zerr I. Clinical findings and diagnostic tests in the MV-2 subtype of sporadic CJD. Brain 129 (2006) 2288-2296
19. Lemstra A.W., van Meegen M.T., Vreyling J.P., Meijerink P.H., Jansen G.H., Bulk S., Baas F., and van Gool W.A. 14-3-3 testing in diagnosing Creutzfeldt-Jakob disease: a prospective study in 112 patients. Neurology 55 (2000) 514-516
20. Meissner B., Westner I., Kallenberg K., Krasnianski A., Bartl M., Varges D., Boesenberg C., Kretzschmar H.A., Knauth M., Schulz-Schaeffer W.J., and Zerr I. Sporadic Creutzfeldt-Jakob disease: clinical and diagnostic characteristics of the rare VV1 type. Neurology 65 (2005) 1544-1550
21. Otto M., Stein H., Szudra A., Zerr I., Bodemer M., Gefeller O., Poser S., Kretzschmar H.A., Maeder M., and Weber T. S-100 protein concentration in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J. Neurol. 244 (1997) 566-570
22. Otto M., Wiltfang J., Cepek L., Neumann M., Mollenhauer B., Steinacker P., Ciesielczyk B., Schulz-Schaeffer W., Kretzschmar H.A., and Poser S. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 58 (2002) 192-197
23. Parchi P., Castellani R., Capellari S., Ghetti B., Young K., Chen S.G., Farlow M., Dickson D.W., Sima A.A.F., Trojanowski J.Q., Petersen R.B., and Gambetti P. Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann. Neurol. 39 (1996) 767-778
24. Parchi P., Giese A., Capellari S., Brown P., Schulz-Schaeffer W., Windl O., Zerr I., Budka H., Kopp N., Piccardo P., Poser S., Rojiani A., Streichemberger N., Julien J., Vital C., Ghetti B., Gambetti P., and Kretzschmar H.A. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann. Neurol. 46 (1999) 224-233
25. Poser S., Mollenhauer B., Krauss A., Zerr I., Steinhoff B.J., Schröter A., Finkenstaedt M., Schulz-Schaeffer W., Kretzschmar H.A., and Felgenhauer K. How to improve the clinical diagnosis of Creutzfeldt-Jakob disease. Brain 122 (1999) 2345-2351
26. Richard M., Biacabe A.G., Perret-Liaudet A., McCardle L., Ironside J.W., and Kopp N. Protection of personnel and environment against Creutzfeldt-Jakob disease in pathology laboratories. Clin. Exp. Pathol. 47 (1999) 192-200
27. Sanchez-Juan P., Green A., Ladogana A., Cuadrado-Corrales N., Sanchez-Valle R., Mitrova E., Stoeck K., Sklaviadis T., Kulczycki J., Hess K., Bodemer M., Slivarichova D., Saiz A., Calero M., Ingrosso L., Knight R., Janssens C., Van Duijn C., and Zerr I. Cerebrospinal fluid tests in the differential diagnosis of CJD. Neurology 67 (2006) 637-643
28. Sanchez-Juan P., Sanchez-Valle R., Green A., Ladogana A., Cuadrado-Corrales N., Mitrova E., Stoeck K., Sklaviadis T., Kulczycki J., Hess K., Krasnianski A., Equestre M., Slivarichova D., Saiz A., Calero M., Pocchiari M., Knight R., van Dujin C.M., and Zerr I. Influence of timing on CSF tests value for Creutzfeldt-Jakob disease diagnosis. J. Neurol. 254 (2007) 901-906
29. Satoh J., Kurohara K., Yukitake M., and Kuroda Y. The 14-3-3 protein detectable in the cerebrospinal fluid of patients with prion-unrelated neurological diseases is expressed constitutively in neurons and glial cells in culture. Eur. Neurol. 4 (1999) 216-225
30. Schulz-Schaeffer W.J., Fatzer R., Varidevelde M., and Kretzschmar H.A. Detection of PrP(Sc) in subclinical BSE with the paraffin-embedded tissue (PET) blot. Arch. Virol. 16 (2000) 173-180
31. Shiga Y., Wakabayashi H., Miyazawa K., Kido H., and Itoyama Y. 14-3-3 protein levels and isoform patterns in the cerebrospinal fluid of Creutzfeldt-Jakob disease patients in the progressive and terminal stages. J. Clin. Neurosci. 6 (2006) 661-665
32. Tourtellotte W.W. The cerebrospinal fluid in multiple sclerosis. In: Vinken P.J., Bruyn G.W., and Klawans H.L. (Eds). Handbook of Clinical Neurology vol. 3 (47) (1985), Elsevier Science Publishers, Amsterdam 79-130
33. Van Everbroeck B., Green A., Pals P., Martin J.J., and Cras P. Decreased levels of amyloid-beta 1-42 in cerebrospinal fluid of Creutzfeldt-Jakob disease patients. J. Alzheimers Dis. 1 (1999) 419-424
34. Van Everbroeck B., Quoilin S., Boons J., Martin J.J., and Cras P. A prospective study of CSF markers in 250 patients with possible Creutzfeldt-Jakob disease. J. Neurol. Neurosurg. Psychiatry 74 (2003) 1210-1214
35. van Hemert M., Steensma H., and van Heusden G. 14-3-3 proteins: key regulators of cell division, signalling and apoptosis. Bioessays 10 (2001) 936-946
36. WHO. Consensus on Criteria for Sporadic CJD (1998), WHO, Geneva. http://www.who.int/emc-documents/tse/docs/whoemczdi989.pdf
37. Windl O., Giese A., Schulz-Schaeffer W., Zerr I., Skworc K., Arendt S., Oberdieck C., Bodemer M., Poser S., and Kretzschmar H.A. Molecular genetics of human prion diseases in Germany. Hum. Genet. 105 (1999) 244-252
38. Xiao B., Smerdon S.J., Jones D.H., Dodson G.G., Soneji Y., Aitken A., and Gamblin S.J. Structure of a 14-3-3 protein and implications for coordination of multiple signalling pathways. Nature 6536 (1995) 188-191
39. Zerr I., Bodemer M., Gefeller O., Otto M., Poser S., Wiltfang J., Windl O., Kretzschmar H.A., and Weber T. Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann. Neurol. 43 (1998) 32-40
40. Zerr I., Bodemer M., Räcker S., Grosche S., Poser S., Kretzschmar H.A., and Weber T. Cerebrospinal fluid concentration of neuron-specific enolase in diagnosis of Creutzfeldt-Jakob disease. Lancet 345 (1995) 1609-1610
41. Zerr I., Pocchiari M., Collins S., Brandel J.P., de Pedro Cuesta J., Knight R.S.G., Bernheimer H., Cardone F., Delasnerie-Lauprêtre N., Cuadrado Corrales N., Ladogana A., Fletcher A., Bodemer M., Awan T., Ruiz Bremón A., Budka H., Laplanche J.L., Will R.G., and Poser S. Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology 55 (2000) 811-815
42. Zerr I., Schulz-Schaeffer W.J., Giese A., Bodemer M., Schröter A., Henkel K., Tschampa H.J., Windl O., Pfahlberg A., Steinhoff B.J., Gefeller O., KH A., and Poser S. Current clinical diagnosis in CJD: identification of uncommon variants. Ann. Neurol. 48 (2000) 323-329